Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments.   23 February 2016
Americas
AstraZeneca has sued Innopharma over its attempt to market a generic version of breast cancer treatment drug Faslodex.   22 February 2016
Big Pharma
The English High Court has rejected Janssen Sciences’ request for a stay in its patent infringement and invalidity dispute with Eli Lilly.   19 February 2016
Europe
The IP landscape in Europe for the CRISPR gene-editing technology is very murky, making it difficult for potential licensees, says Catherine Coombes of HGF.   18 February 2016
Americas
The US Federal Trade Commission has waded into a competition dispute at the US Court of Appeals for the Federal Circuit centring on ‘reverse payment’ settlements.   18 February 2016
Americas
During nearly 30 years as a US Supreme Court justice, Antonin Scalia had the unenviable tasks of ruling on homosexuality, the right to carry hand guns, and abortion. Nevertheless, it was a mystery patent case that proved the most difficult. WIPR looks back at some of the most important IP cases of the past few years and how Scalia voted on them.   18 February 2016
Americas
Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.   17 February 2016
Americas
Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.   17 February 2016
Americas
Law firm Reed Smith has expanded its intellectual property, information and innovation group by hiring Lisa Chiarini as a partner in New York.   17 February 2016
Americas
Accord Healthcare’s attempt to market a generic version of Pfizer’s Tygacil has hit a brick wall after it was accused of infringing three patents.   16 February 2016